Сара Хилл - Вы и ваши гормоны

212.Ernst, U., Baumgartner, L., Bauer, U., & Janssen, G. (2002). Improvement of quality of life in women using a low-dose desogestrel-containing contraceptive: Results of an observational clinical evaluation. European Journal of Contraception and Reproductive Health Care, 7 (4), 238–243. doi: 10.1080/ejc.7.4.238.243.

213.Poromaa, I. S., & Segebladh, B. (2012). Adverse mood symptoms with oral contraceptives. Acta Obstetricia et Gynecologica Scandinavica, 91 (4), 420–427. doi: 10.1111/j.­1600-0412.­2011.­01333.x; Freeman, E. W., Kroll, R., Rapkin, A.et al. (2001). Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women’s Health and Gender-Based Medicine, 10 (6), 561–569. doi: 10.1089/­152­460­901­525­431­48; Parsey, K. S., & Pong, A. (2000). An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception, 61 (2), 105–111. doi: 10.1016/s0010-7824(00)00083-4; Sillem, M., Schneidereit, R., Heithecker, R., & Mueck, A. O. (2009). Use of an oral contraceptive containing drospirenone in an extended regi­men. European Journal of Contraception and Reproductive Health Care, 8 (3), 162–169. doi: 10.1080/­ejc.­8.3.­162.­169; Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8 (1), 37–51. doi: 10.1080/­713­604­397.

214.Deijen, J., Duyn, K., Jansen, W., & Klitsie, J. (1992). Use of a monophasic, low-dose oral contraceptive in relation to mental functioning. Contraception, 46 (4), 359–367. doi: 10.1016/­0010-7824­(92)­90098-e.

215.Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg30 and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5 (4), 251–256. doi: 10.2165/­000­246­77-200­605­040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29 (3), 153–159. doi: 10.2165/­000­440­11-2009­29­030-00002.

216.Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18 (1), 103–111. doi: 10.1007/­s00737-014-0453-4; Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews . doi: 10.1002/­1465­1858.­cd00­6586.

217.Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70 (3), 229–240. doi: 10.1016/­s0165-0327­(01)­00356-1.

218.Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8 (1), 37–51. doi: 10.1080/­7136­04397; Chiou, C., Trussell, J., Reyes, E. et al. (2003). Economic analysis of contraceptives for women. Contraception, 68 (1), 3–10. doi: 10.1016/­s0010-7824­(03)­00078-7; Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (2001). Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. Journal of Clinical Psychopharmacology, 21 (5), 540–542. doi: 10.1097/00004714-200110000-00018; Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg 30and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5 (4), 251–256. doi: 10.2165/­0002­4677-2006­05040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29 (3), 153–159. doi: 10.2165/­0004­4011-2009­29­030-00002.

219.Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews . doi: 10.1002/­1465­1858.­cd00­6586. Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18 (1), 103–111. doi: 10.1007/­s00737-014-0453-4.

220.Kurshan, N., & Epperson, C. N. (2006). Oral contraceptives and mood in women with and without premenstrual dysphoria: A theoretical model. Archives of Women’s Mental Health, 9 (1), 1–14. doi: 10.1007/­s00737-005-0102-z; Genazzani, A. R., Stomati, M., Morittu, A.et al. (2000). Progesterone, progestagens and the central nervous system. Human Reproduction, 15 (Suppl. 1), 14–27. doi: 10.1093/­humrep/­15.suppl_­1.14; Rapkin, A., Morgan, M., Goldman, L. et al. (1997). Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstetrics and Gynecology, 90 (5), 709–714. doi: 10.1016/­s0029-7844­(97)­00417-1; Sundström, I., Andersson, A., Nyberg, S. et al. (1998). Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology, 67 (2), 126–138. doi: 10.1159/­000­054­307.

221.Abraham, S., Luscombe, G., & Soo, I. (2003). Oral contraception and cyclic changes in premenstrual and menstrual experiences. Journal of Psychosomatic Obstetrics and Gynecology, 24 (3), 185–193. doi: 10.3109/­016­748­203­090­396­72; Bäckström, T., Hansson-Malmström, Y., Lindhe, B. et al. (1992). Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception, 46 (3), 253–268. doi: 10.1016/­0010-7824­(92)­90006-f; Svendal, G., Berk, M., Pasco, J. A. et al. (2012). The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140 (1), 92–96. doi: 10.1016/­j.jad.­2012.­03.030; Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70 (3), 229–240. doi: 10.1016/­s0165-0327­(01)­00356-1.

Глава 9

222.Khalili, H., Granath, F., Smedby, K. E. et al. (2016). Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology, 150 (7), 1561–1567.e1. http://doi.org/­10.1053/­j.gastro.­2016.­02.­041; Khalili, H., Higuchi, L. M., Ananthakrishnan, A. N. et al. (2013). Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut, 62 (8), 1153–1159. http://doi.org/­10.1136/­gutjnl-2012-302362.

223.Falony, G., Joossens, M., Vieira-Silva, S. et al. (2016). Population-level analysis of gut microbiome variation. Science, 352 (6285), 560–564. doi: 10.1126/­science.­aad3503.

224.Fichorova, R. N., Chen, P., Morrison, C. S. et al. (2015). The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception. mBio, 6 (5). doi: 10.1128/­mbio.­00221-15.